Evercore ISI analyst Daniel Markowitz had a “Tactical Outperform” call on West Pharmaceutical (WST) heading into earnings, but is removing it from the firm’s TAP list given that West reported earnings late last week. The firm has an Outperform rating and $390 price target on the shares.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on WST:
- West Pharmaceutical price target raised to $325 from $275 at Barclays
- West Pharmaceutical price target raised to $370 from $310 at BofA
- West Pharmaceutical price target raised to $355 from $320 at UBS
- West Pharmaceutical price target raised to $345 from $305 at Deutsche Bank
- West Pharmaceutical Services Reports Strong Q3 2025 Results